Knowledge Center

GenMark Diagnostics Provides Preliminary Financials for First Quarter and Increases Guidance for 2020

On April 7, GenMark Diagnostics, Inc. (GNMK) provided preliminary financial results for the quarter ending March 31, 2020. During the first quarter, GenMark received FDA emergency use authorization for its ePlex SARS-CoV-2 Test. Total revenue estimates for the first quarter are $38.7 million, which is an 80% increase over the first quarter of 2019. GenMark […]

Read more...

Scientific Games Wins 10-year Iowa Lottery Contract

Scientific Games Corporation (SGMS) announced on April 7 that the company won a new 10-year contract with the Iowa Lottery. Scientific Games will provide a new statewide gaming system for the 2,400 retail locations where Iowa Lottery games are sold. Over the last eight years, Scientific Games has helped the Iowa Lottery to increase sales […]

Read more...

March 2020 Scorecard

The March 2020 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

New York State Department of Financial Services Reapproves China Oceanwide’s Acquisition of Genworth Life Insurance

New York State Department of Financial Services reapproved a previous proposal for China Oceanwide Holdings Group Co. Ltd. (Oceanwide)’s acquisition of Genworth Life Insurance Company of New York (GLICNY). Genworth Financial, the parent company of Genworth Life Insurance, reported the news with Oceanwide on March 24. The New York State Department of Financial Services had […]

Read more...

Fortress Biotech Announces Preferred Share Repurchase Program

On March 23, Fortress Biotech (FBIOP) reported that its Board of Directors authorized a share repurchase program. Under the terms of the agreement, Fortress Biotech can repurchase up to $5 million of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. Fortress Biotech appointed ThinkEquity to purchase the stock on behalf of the company in […]

Read more...

Advanz Pharma Acquires Correvio Pharma

On March 16, Correvio Pharma Corp. (CORV) announced that the company signed an acquisition agreement with Advanz Pharma Corp. Limited (ADVZ). Advanz Pharma will pay approximately $76 million for all outstanding Correvio shares and will execute the acquisition through its wholly-owned subsidiary, Mercury Pharma Group Limited. Correvio is a specialty pharmaceutical company focusing on commercializing […]

Read more...

Heritage Financial’s Board of Directors Authorizes New Share Repurchase Program

On March 12, Heritage Financial Corporation (HFWA) announced that the company’s Board of Directors authorized a new share repurchase program. This new stock repurchase program follows one authorized in 2014 in which the company repurchased 1,512,600 shares of common stock. The new program allows Heritage Financial to repurchase approximately 1.8 million shares, or up to […]

Read more...

February 2020 Scorecard

The February 2020 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Gilead Sciences Acquires Forty Seven Inc. for $4.9 Billion

On March 2, Gilead Sciences Inc. (GILD.O) announced that it will acquire Forty Seven Inc. (FTSV.O) for $4.9 billion in cash. Gilead Sciences was particularly interested in adding an experimental treatment targeting blood cancer to its portfolio of oncology drugs. Forty Seven’s leading drug, magrolimab, switches off the CD47 signal that allows tumor cells to […]

Read more...

Thermo Fisher Scientific Acquires Qiagen

On March 3, Thermo Fisher Scientific Inc. (TMO) and Qiagen N.V. (QGEN) announced that the Board of Directors from both companies approved Thermo Fisher’s proposal to acquire Qiagen. Under the terms of the agreement, Thermo Fisher will pay €39 per share in cash for Qiagen, which values the company at around $11.5 billion. Qiagen is […]

Read more...